ORIC Pharmaceuticals enters today's earnings report with nearly 30% of its free float sold short — a meaningful bearish overhang for a clinical-stage biotech that has rallied 8% over the past month.
Short sellers are firmly committed heading into the print. SI % of FF has held in a tight band around 29–30% for the past six weeks, briefly touching 32% in early April before edging back. The week-on-week change of roughly 7% suggests incremental accumulation rather than a decisive exit. Yet despite the elevated short base, the borrow market tells a looser story: the cost to borrow has actually eased sharply, dropping nearly 30% over the past week to just 0.46% — a negligible rate that removes any squeeze mechanic from the equation. Availability has also been relatively generous, with borrow utilisation well off the early-April peak near 45% and now closer to 26%. The high short position, paired with cheap borrow, points to bears who are comfortable sitting on these positions without pressure to cover. Options positioning reinforces the bullish lean in the near term: the put/call ratio has collapsed to 0.07, far below its 20-day average of 0.18, suggesting call activity is dominating the options market into the catalyst.
The bull and bear debate here is ultimately a binary clinical argument. Bulls point to an upcoming pipeline of data catalysts across 2026 — combination data from ORIC-944 in mCRPC and updates for both ORIC-944 and enozertinib — with analysts at HC Wainwright and Piper Sandler maintaining targets between $22 and $25 against a current price of $9.63. Wedbush trimmed its target to $17 from $20 in early April while keeping an Outperform rating, a signal that conviction on direction remains intact even as valuation assumptions are recalibrated. Bears counter that the withdrawal of Ipsen's tazemetostat has raised pointed questions about EZH2 inhibition as a class, and that enozertinib has yet to deliver confirmed responses. The ORTEX short score of 73 places ORIC in the 8th percentile of its universe — meaning very few stocks carry a more bearish short-market signal. The mean analyst price target near $21 implies more than 100% upside from current levels, though those figures reflect consensus struck in early April and investors should weigh them accordingly.
Institutional ownership is deeply concentrated in specialist biotech funds. Nextech, EcoR1, and Viking Global are the three largest holders, each above 6.5%. BlackRock added 598K shares in Q1, and T. Rowe Price built a 800K-share position in the same period — passive and active flows both trending constructive at the institutional level, even as short interest has climbed.
Today's report is less a financial event — the company burns cash and carries no meaningful revenue multiples — and more a clinical credibility check, with investors focused on whether the pipeline narrative can hold up against the EZH2 class concerns that have given short sellers their primary thesis.
See the live data behind this article on ORTEX.
Open ORIC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
